<DOC>
	<DOCNO>NCT00656786</DOCNO>
	<brief_summary>This clinical research study experimental new medication , Menadione Topical Lotion ( MTL ) . The study lotion experimental approve public use . Hana Biosciences , Inc. , company develop MTL , sponsor study . EGFR inhibitor use treat non-small cell lung cancer ( NSCLC ) , pancreatic cancer , colorectal cancer , breast cancer head neck cancer . One side effect EFGR inhibitor skin toxicity include acneform skin rash . This study Phase 1 study . The main purpose study : - Evaluate safety tolerability Menadione Topical Lotion emergent pre-emergent treatment EGFR inhibitor-associated rash - Evaluate systemic absorption bioavailability Menadione Topical Lotion emergent pre-emergent treatment EGFR inhibitor-associated rash It plan 24 patient undergoing EGFR inhibitor therapy take part study multiple clinical center .</brief_summary>
	<brief_title>Safety , Tolerability Systemic Absorption Menadione Topical Lotion Epidermal-Growth-Factor-Receptor ( EGFR ) Inhibitor-Associated Rash</brief_title>
	<detailed_description />
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Vitamin K 3</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>1 . Male female subject least 18 year old ; 2 . Have prescribe approve EGFRI treat cancer expect begin treatment within 14 day ( i.e. , EGFRI approve treatment cancer time subject enrollment ) ; 3 . For Group 1 : Agree return clinic Visit 3 first acute sign symptom rash ( papular and/or pustular eruption and/or nodule ) face/neck and/or upper chest suspect related EGFRI therapy within 21 day start EGFRI therapy ; For Group 2 : Expect start EGFRI therapy one day start treatment study lotion ; 4 . Have Eastern Cooperative Oncology Group ( ECOG ) performance rating ≤ 2 ( see Appendix 1 ) ; 5 . Have life expectancy least 4 month ; 6 . Males non pregnant , nonlactating female postmenopausal , naturally surgically sterile , agree use effective contraceptive method throughout course study . Postmenopausal define least 12 month natural spontaneous amenorrhea , least 6 week follow surgical menopause ( bilateral oophorectomy ) ; 7 . Females childbearing potential male female sexual partner childbearing potential must agree use one follow acceptable birth control method : 1 . Surgically sterile ( hysterectomy bilateral oophorectomy ) ; 2 . Surgically sterile ( bilateral tubal ligation surgery least 6 week prior study initiation ) . Documentation require ; 3 . Intrauterine device place least 3 month ; 4 . Doublebarrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; 5 . Stable hormonal contraceptive ( oral , topical , vaginal implanted//injected ) least 3 month prior study study completion ; 6 . Abstinence ; 7 . Singlebarrier method least 14 day prior screen study completion vasectomize male female vasectomized partner ; 8 . Able understand provide sign informed consent ; 9 . Females childbearing potential must negative serum βhuman chorionic gonadotropin ( hCG ) pregnancy test Visit 1 negative urine βhCG pregnancy test Visit 3 ( Group 1 ) Visit 2 ( Group 2 ) . Subjects meet follow criterion eligible enrollment . 1 . A skin examination reveals presence active disease ( e.g. , eczema ) , tattoos problem , open lesion , could make application site unacceptable study drug lotion application , locate face/neck and/or upper chest , Investigator 's opinion , could confound evaluation rash ; 2 . Any clinically significant safety laboratory diagnostic result , opinion Investigator , would place subject undue risk subject participate study ; 3 . Any clinically significant find concurrent clinical illness physical examination medical history , opinion Investigator , would place subject undue risk subject participate study ; 4 . Undergoing current treatment cancer prescribe EGFRI opinion Investigator , would place subject undue risk subject participate study ; 5 . Prior treatment market investigational EGFRI therapy within 3 month prior screen ( Visit 1 ) ; 6 . Treatment topical antibiotic , topical steroid , topical treatment face/neck upper chest within 14 day first study lotion application ; 7 . Systemic use steroid stop Visit 1 allow course study ; 8 . Treatment vitamin K supplement multivitamins contain form vitamin K stop Visit 1 ; 9 . Known hypersensitivity menadione similar compound include inactive ingredient ; 10 . Treatment oral anticoagulant therapy ( i.e. , Warfarin ) ; 11 . Any subject prior history bleed hematologic disorder ; 12 . Clinically significant abnormal laboratory value screen , include limited follow hematologic , renal liver function laboratory value : 1 . Hematologic function : Hemoglobin &lt; 9.0 gL/dL &lt; 10.0 g/dL subject receive hematopoietic growth factor , darbopoeitin alfa epoetin alfa ANC &lt; 1,500/mm3 ( &lt; 1.5 ×109/L ) Platelet count &lt; 100,000/mm3 ( &lt; 100 ×109/L ) 2 . Renal function : • Serum creatinine &gt; 1.5 mg/dL &lt; 133 umol/L ( SI unit ) calculate estimate creatinine clearance &lt; 60 ml/min/1.73 m2 base Cockcroft Gault formula 3 . Hepatic function : Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 3 × institutional upper limit normal ( ULN ) &gt; 5 × institutional ULN document liver metastasis Total bilirubin &gt; 2 × institutional ULN &gt; 5 × institutional ULN document liver metastasis 13 . Treatment cosmetic cream , makeup product sun screen , oil , powder , perfume , lotion , ointment , etc . anticipate study lotion application area within 3 day treatment treatment period ; 14 . Known suspected pregnancy , lactation plan pregnancy ( female male ) ; 15 . Clinically significant mental illness ( determined Investigator ) ; 16 . Exposure investigational agent within 2 week 3 halflives prior randomization ( Visit 3 , Day 1 Group 1 Visit 2 , Day 1 Group 2 ) ; 17 . The subject disqualify rash longer 5 day grade 3 prior administration first menadione dose ( per CTCAE v3.0 terminology [ see Appendix 2 ] ) ; 18 . Subject condition Investigator believe would interfere ability provide inform consent comply study instruction , might confound interpretation study result put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>